The European Medicines Agency granted an orphan drug designation to ImMucin for the treatment of multiple myeloma. ImMucin targets the less studied signal peptide domain of the MUC1 tumor antigen.
A new study found that capping the cost-sharing for prescription drugs on individual policies in the health insurance marketplace would reduce patients' annual out-of-pocket healthcare spending, and have a small effect on insurance premiums while allowing insurers to remain compliant with the law.
FDA granted Orphan Drug Designation for Reolysin for the treatment of cancer of the fallopian tube.
FDA granted Fast Track Designation for HS-410 (vesigenurtacel-L) for the treatment of non-muscle invasive bladder cancer.
FDA approved Unituxin (dinutuximab) as part of first-line therapy for pediatric patients with high-risk neuroblastoma.
Array BioPharma Inc. announced the completion of both the binimetinib and encorafenib definitive agreements with Novartis.
Amgen launched the Neulasta (pegfilgrastim) Delivery Kit in the U.S.
Bristol-Myers Squibb Co. and Bavarian Nordic formed an agreement providing Bristol-Myers Squibb an exclusive option to license and commercialize Prostvac, Bavarian Nordic's investigational phase III prostate-specific antigen targeting immunotherapy in development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer, in a deal worth up to $975 million.
AbbVie announced a definitive agreement to acquire Pharmacyclics and its flagship asset Imbruvica for $21 billion. Under the terms of the transaction, announced March 4, AbbVie will pay$261.25 per share, comprised of a mix of cash and AbbVie equity.
FDA launched a mobile application designed to speed public access to information about drug shortages. The app identifies current drug shortages, resolved shortages and discontinuations of drug products.
